3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors
US11802127B2 · kind B2 · utility
0Cited by
1References
53Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 30, 2022 |
| Grant date | Oct 31, 2023 |
| Priority date | — |
| Expiry date | May 18, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof. The invention further relates to solid forms of 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.